Kahán Z - Search Results

1

Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.

Pipek O, Alpár D, Rusz O, Bödör C, Udvarnoki Z, Medgyes-Horváth A, Csabai I, Szállási Z, Madaras L, Kahán Z, Cserni G, Kővári B, Kulka J, Tőkés AM. Pipek O, et al. Among authors: kahan z. Int J Mol Sci. 2023 May 10;24(10):8553. doi: 10.3390/ijms24108553. Int J Mol Sci. 2023. PMID: 37239898 Free PMC article.

2

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.

3

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.

Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Kahán Z, et al. Cancer. 1999 Jun 15;85(12):2608-15. Cancer. 1999. PMID: 10375109

4

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Kahán Z, et al. Breast Cancer Res Treat. 2000 Feb;59(3):255-62. doi: 10.1023/a:1006352401912. Breast Cancer Res Treat. 2000. PMID: 10832595

5

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.

Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T. Zielinski C, et al. Among authors: kahan z. J Clin Oncol. 2005 Mar 1;23(7):1401-8. doi: 10.1200/JCO.2005.12.106. J Clin Oncol. 2005. PMID: 15735116 Clinical Trial.

6

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z. Nagy A, et al. Among authors: kahan z. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1794-9. doi: 10.1073/pnas.95.4.1794. Proc Natl Acad Sci U S A. 1998. PMID: 9465096 Free PMC article.

7

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.

Kahán Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, Robinson WR, Schally AV. Kahán Z, et al. J Clin Endocrinol Metab. 1999 Feb;84(2):582-9. doi: 10.1210/jcem.84.2.5487. J Clin Endocrinol Metab. 1999. PMID: 10022420

8

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.

Kahán Z, Varga JL, Schally AV, Rékási Z, Armatis P, Chatzistamou L, Czömpöly T, Halmos G. Kahán Z, et al. Breast Cancer Res Treat. 2000 Mar;60(1):71-9. doi: 10.1023/a:1006363230990. Breast Cancer Res Treat. 2000. PMID: 10845811

9

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.

Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.

10

Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.

Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G. Kahán Z, et al. Cancer. 2000 Mar 15;88(6):1384-92. doi: 10.1002/(sici)1097-0142(20000315)88:6<1384::aid-cncr16>3.0.co;2-q. Cancer. 2000. PMID: 10717621

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page